ADIL: Adial Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ADIL: Adial Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.26
Enterprise Value ($M) 4.43
Book Value ($M) 4.08
Book Value / Share 1.01
Price / Book 1.78
NCAV ($M) 2.55
NCAV / Share 0.63
Price / NCAV 2.85

Profitability (mra)
Return on Invested Capital (ROIC) -1.25
Return on Assets (ROA) -1.31
Return on Equity (ROE) -3.56

Liquidity (mrq)
Quick Ratio 4.90
Current Ratio 4.90

Balance Sheet (mrq) ($M)
Current Assets 3.20
Assets 4.74
Liabilities 0.65
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -6.89
Net Income -5.12
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -6.81
Cash from Investing 1.50
Cash from Financing 4.13

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-10-30 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A AMENDMENT NO.1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REP
2023-08-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-12 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 28,343 105,280 26.92
2024-05-02 37,991 45,428 83.63
2024-05-01 12,152 17,607 69.02
2024-04-30 49,364 34,500 143.08
2024-04-29 45,922 26,502 173.28

(click for more detail)

Similar Companies
ACHV – Achieve Life Sciences, Inc. ACST – Acasti Pharma Inc.
ACXP – Acurx Pharmaceuticals, Inc. ADTX – Aditxt, Inc.
ADVM – Adverum Biotechnologies, Inc.


Financial data and stock pages provided by
Fintel.io